• In August 2026, Charles River Laboratories International reported second-quarter results showing revenue of US$1,004.08 million and a small net loss of US$1.48 million, while also lowering its 2026 GAAP EPS guidance to US$3.05–US$3.35 per share and projecting a 2.5%–3.5% revenue decline due mainly to divestiture-related losses.
• Despite the weaker GAAP outlook, management highlighted a return to organic revenue growth and improving demand in its Discovery and Safety Assessment segment, supported by stronger biopharmaceutical activity and expanded collaborations.
• We’ll now examine how this combination of lower GAAP guidance and recovering Discovery and Safety Assessment demand may reshape Charles River’s investment narrative.

Uncover the next big thing with 18 elite penny stocks that balance risk and reward.

Charles River Laboratories International Investment Narrative Recap

To own Charles River today, you have to believe that a recovery in biopharma demand and the Discovery and Safety Assessment (DSA) franchise can offset divestiture noise and current losses. The lowered 2026 GAAP EPS guidance and modest revenue decline sharpen the near term focus on whether DSA’s organic growth can sustain, while the main risk remains demand volatility in R&D spending rather than the divestiture-related GAAP hit itself, which looks more optical than operational.

Against that backdrop, the ongoing share repurchase program, which has retired about 5% of shares for roughly US$450.7 million so far, is the announcement that most directly intersects with this quarter’s story. It reinforces how much confidence you think is justified in a return to profitability and organic growth, because shrinking the share count while GAAP earnings are under pressure can magnify both the upside from a sustained DSA recovery and the downside if demand weakens again.

Yet behind the improving DSA bookings, investors should be aware that the biggest swing factor may still be...

Charles River Laboratories International's narrative projects $4.1 billion revenue and $461.2 million earnings by 2029. This requires fairly flat yearly revenue growth and a $645.9 million earnings increase from -$184.7 million today.

Uncover how Charles River Laboratories International's forecasts yield a $230.93 fair value, a 18% downside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming roughly flat revenues and only about US$363.0 million of earnings by 2029, and this quarter’s small GAAP loss could reinforce their view that even with DSA stabilizing, Charles River’s path to those margins is less certain than the consensus narrative suggests.

Explore 4 other fair value estimates on Charles River Laboratories International - why the stock might be worth as much as 14% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Charles River Laboratories International research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Charles River Laboratories International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Charles River Laboratories International's overall financial health at a glance.

Ready For A Different Approach?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 50 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 44 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.